Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ensysce Biosciences Inc.

    NASDAQ: ENSC · Real-Time Price · USD
    2.20
    -0.27 (-10.93%)
    At close: May 06, 2025, 3:59 PM
    2.17
    -1.31%
    After-hours: May 06, 2025, 07:41 PM EDT
    -10.93%
    Bid 2.11
    Market Cap 3.62M
    Revenue (ttm) 487.52K
    Net Income (ttm) -7.99M
    EPS (ttm) -11.45
    PE Ratio (ttm) -0.19
    Forward PE 0.06
    Analyst n/a
    Ask 2.38
    Volume 160,077
    Avg. Volume (20D) 1,669,205
    Open 2.32
    Previous Close 2.47
    Day's Range 2.13 - 2.32
    52-Week Range 1.62 - 14.67
    Beta 1.07

    About ENSC

    Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date Mar 14, 2018
    Employees 7
    Stock Exchange NASDAQ
    Ticker Symbol ENSC
    Website https://www.ensysce.com
    Full Company Profile

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    +96.26%
    Ensysce Biosciences shares are trading higher afte... Unlock content with Pro Subscription
    5 months ago
    +14.48%
    Ensysce Biosciences shares are trading higher after the company announced treatment for its first group of subjects in the PF614-MPAR-102 study.
    news image

    1 week ago · accessnewswire.com

    Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

    SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain reli...

    news image

    1 week ago · benzinga.com

    Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

    Ensysce Biosciences, Inc ENSC stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as per data from Benzinga Pro.

    news image

    2 weeks ago · accessnewswire.com

    Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

    SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain reli...

    news image

    1 week ago · accessnewswire.com

    Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

    ~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~ ~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, In...

    news image

    3 weeks ago · accessnewswire.com

    Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

    ~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensy...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for sev...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

    ~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce B...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

    Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / ...

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

    SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for seve...

    Add to Watchlist